The International Society of Aesthetic Plastic Surgery (ISAPS) publishes annual cosmetic procedure statistics — and Korea consistently ranks first globally per capita. The 2025 data confirms Korea\'s position with 13.5 procedures per 1,000 people, far exceeding any other country. This article examines the data and what it reveals about Korean cosmetic surgery in 2026.
The 2025 ISAPS data summary
Korea\'s global ranking
- First globally per capita.
- 13.5 procedures per 1,000 individuals.
- 8.90 procedures per 1,000 residents (different metric reported).
- Total procedures: significant but not highest globally.
- Brazil and U.S. higher in absolute volume.
Why per capita matters more
- Cultural acceptance reflected.
- Industry maturity indicator.
- Per-population engagement metric.
- Korean cultural distinction.
Top procedures in Korea
Surgical procedures
- Rhinoplasty: ~30% of procedures.
- Eyelid surgery (blepharoplasty): major share.
- Facial contouring (V-line, jaw): significant volume.
- Breast surgery: substantial.
- Liposuction: increasing.
Non-surgical procedures
- Botulinum toxin: massive volume.
- Hyaluronic acid filler: enormous market.
- Laser treatments: growing.
- Skin boosters and injectables: explosive growth.
- Energy-based devices (HIFU, RF): expanding.
Market size data
- South Korea Cosmetic Surgery and Procedures Market projected to USD 12.14 Bn by 2034.
- Strong growth trajectory.
- International patient market substantial.
- Domestic market mature.
- Continued investment from clinics.
2025–2026 trend shifts
Toward non-surgical
- Industry shift to non-invasive treatments.
- Botox and fillers dominant in volume.
- Energy devices expanding.
- Patient preference for less downtime.
Toward natural results
- "Bespoke Glow" 2026 trend.
- Subtle enhancement over dramatic transformation.
- Cookie-cutter aesthetics declining.
- Personalization emphasis.
Toward regenerative medicine
- Exosome therapy mainstreaming.
- Stem cell-derived treatments.
- PRP and PRF expanding.
- Long-term skin investment.
Toward technology integration
- 3D imaging routine.
- AI-driven simulation.
- Custom 3D-printed implants.
- Robotic-assisted procedures emerging.
Patient demographics
Age distribution
- Teenagers and young adults: substantial share.
- 20s-30s: largest cohort.
- 40s-50s: growing for anti-aging.
- 60+: increasing for facelift and rejuvenation.
Gender breakdown
- Female: still majority.
- Male: 20–40% at cosmetic clinics now.
- Male engagement growing rapidly.
- Gender norms evolving.
International patients
- Substantial and growing.
- Asian markets: China, Japan, SE Asia primary.
- Western markets: U.S., Australia, Europe expanding.
- Middle Eastern market growing.
- Diaspora returning patients significant.
Procedure-specific 2025 data
Surgical (Korean per capita estimated)
- Rhinoplasty: very high (~3.8 per 1,000).
- Blepharoplasty: extremely high (~2.5 per 1,000).
- Facial contouring: substantial (~1.8 per 1,000).
- Breast augmentation: moderate (~0.7 per 1,000).
- Liposuction: moderate-high (~1.5 per 1,000).
Non-surgical (Korean per capita estimated)
- Botulinum toxin: massive (~10+ per 1,000).
- HA filler: large (~5+ per 1,000).
- Laser treatments: substantial.
- Skin boosters: rapidly growing.
Industry employment
- Substantial number of board-certified plastic surgeons.
- Larger number of cosmetic-practicing physicians.
- Significant nursing and clinical staff.
- Industry support: implant manufacturers, distributors, medical tourism agencies.
- Major Korean economic sector.
2025 regulatory developments
Implemented
- VAT refund for cosmetic surgery abolished (January 2026).
- CCTV mandates for operating rooms (specific procedures).
- Increased enforcement against ghost surgery.
- Foreign patient solicitation regulations strengthened.
Under consideration
- Medical malpractice criminal penalty modifications.
- Foreign-language marketing regulations.
- Mental health screening requirements.
- Industry self-regulation enhancements.
Comparison with global market
Versus other major markets
- U.S.: highest absolute volume but lower per capita.
- Brazil: second-highest absolute volume.
- Japan: third-highest absolute volume.
- Korea: highest per capita.
- Turkey: rapidly growing as competitor for medical tourism.
- Thailand: regional medical tourism player.
Korean specialty
- Eye and nose procedures over-represented.
- Facial contouring near-unique global volume.
- Non-surgical aesthetic medicine dominant.
- Korean techniques exported globally.
What the 2025 data tells us
Cultural integration
- Cosmetic surgery thoroughly normalized in Korea.
- Cultural conversation evolving but practice continues.
- Industry stable and growing.
- International recognition maintained.
Technical excellence
- Korean techniques contributing to global practice.
- Refined approaches to specific procedures.
- Patient outcomes generally high quality.
- Specialty differentiation.
Market sustainability
- Mature domestic market.
- International patient growth offsetting demographic factors.
- Aging Korean population creating new demand for anti-aging.
- Industry adaptation.
Patterns of concern
From the data
- Per capita volume highest globally.
- Pressure on younger Koreans documented.
- Mental health implications real.
- Industry concentration in Gangnam district.
- International marketing intensity.
Required examination
- Long-term outcomes data.
- Patient satisfaction over years.
- Mental health impact studies.
- Industry oversight effectiveness.
What 2025 means for 2026 patients
- Mature, capable industry to access.
- Increasing technology integration.
- Better non-surgical options.
- Continued cost competitiveness.
- Improved patient protection regulations.
- More personalized approaches.
For international patients
- Korean industry remains globally leading.
- Quality competition intense.
- Verification matters more than ever.
- VAT refund changes affect pricing.
- Patient protection improving.
The honest framing
The 2025 ISAPS data confirms what observers have known: Korea remains the global per capita leader in cosmetic procedures, with mature techniques, diverse patient populations, and continued industry innovation. The patients accessing this market in 2026 benefit from Korea\'s technical excellence and competitive pricing — but should approach with the same vetting rigor that any major medical decision requires. The data shows scale and capability; it doesn\'t guarantee individual outcomes. Korean cosmetic surgery is a substantial industry that requires careful patient navigation, and the data confirms it\'s a meaningful global option for the right patients with appropriate planning.